The Zou lab published a paper in Physiological Reports entitled “Pharmacological inhibition of dynamin-related protein 1 attenuates skeletal muscle insulin resistance in obesity”. In this paper, we used a pharmacological inhibitor of Dynamin-Related Protein (Drp1), Mdivi-1, in diet-induced obese mice and human skeletal muscle cells from severely obese humans. We found that pharmacological inhibition of Drp1 was effective to improve skeletal muscle insulin signaling and whole-body glucose homeostasis and insulin sensitivity. Our study builds on existing evidence that Drp1 is associated with skeletal muscle insulin resistance and demonstrates for the first time that inhibiting Drp1 in vivo is an effective strategy to improve skeletal muscle insulin sensitivity and whole-body metabolic health. To read the full article, check it out on the journal website.